Conmed Corporation · NYSE:CNMD
Conmed — J.P. Morgan 43rd Annual Healthcare Conference (January 2025)
12 slides from Conmed's conference presentation, Jan 13, 2025
Slide 1: J.P. Morgan 43rd Annual Healthcare Conference
J.P. Morgan 43rd Annual Healthcare Conference
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statemen
Slide 3: CONMED Vision
CONMED Vision Empower healthcare providers worldwide to deliver exceptional outcomes for patients. Focus behind the Vision People, Products, Profitability J.P. Morgan 43rd Annual Healthcare Conference 3
Slide 4: CONMED Senior Leadership Team
CONMED Senior Leadership Team Ed Clifford VP, Global Manufacturing CON years CONMED: 1.5 years – Industry: 10 years CON ears Todd Garner Pr EVP, Finance & Chief Financial Officer CON ears CONMED: 7 years – Industry: 23 years EVP, Inf CIO VP, Qual fairs CON s CON ears CON ears EVP, etary CON ears C e
Slide 5: Objectives for Our Shareholders
Objectives for Our Shareholders • Aggregate growth and profitability over the long term to significantly increase the valuation of the company • Evolve product mix toward higher-growth, higher-margin offerings • Increase our market share in large and attractive markets • Deliver above-market revenue
Slide 6: Orthopedics: Large, Attractive Markets
Orthopedics: Large, Attractive Markets Category Description Dollar Value of 1 Market Market Size and Competitors Share Point $5.1 to $5.3 Billion Comprehensive portfolio of devices Sports for repair and healing of soft tissue â–ª Arthrex â–ª Zimmer Biomet Medicine & injuries, including implants, bio
Slide 7: General Surgery: Large, Attractive Markets
General Surgery: Large, Attractive Markets Category Description Dollar Value of 1 Market Market Size and Competitors Share Point A platform of devices and accessories $1.5 to $1.7 Billion to create and enter the surgical â–ª Ethicon (J&J) â–ª Medtronic Access ~$16M working space in minimally invasiv
Slide 8: Mix & Gross Margins
Mix & Gross Margins Mid-Term Expected Estimated Category Revenue Growth 2024 GM % Sports Medicine Mid Single Digits to Sept 2024 YTD 65% (including BioBrace) High Single Digits Ortho Capital & Low Single Digits 40% Related Disp. Other Foot & Ankle Double Digits 80% G.I. Sports Total Orthopedics 4% t
Slide 9: Historical Performance
Historical Performance Revenue (in millions) Adjusted EPS $1,300 $4.00 $1,245 to to $1,305 $3.45 $4.05 $1,045* $3.21 $1,011 $955 $860 $862 $2.64 $2.65* $796 $764 $719 $2.18 $2.18 $1.98 $1.89 $1.84 * * 2024 Guidance Range Revenue 2024 Guidance Range Adjusted EPS *2022 results were negatively impacted
Slide 10: Key Focus Areas
Key Focus Areas • Driving superior outcomes for • Protecting caregivers worldwide using patients through clinical insufflation Buffalo Filter’s proprietary technology with AirSeal in Robotic and Laparoscopic surgery • Improving our ability to serve • Delivering superior clinical outcomes in customer
Slide 11: Environmental, Social and Governance
Environmental, Social and Governance Together We Are Making A Difference for a Better Tomorrow Environmental Social Governance CONMED manufacturing Partners with United Way and In addition to oversight by the full operations have recycling TEAMFund to serve communities Board, the ESG Steering progra
Slide 12: Closing Thoughts
Closing Thoughts • 2024 was a challenging year • Intense focus on solving unmet needs for healthcare customers drives increased market share • Large and attractive markets provide CONMED with ample opportunities for above-average revenue and profitability growth • Portfolio continues to evolve towar
CONMED — J.P. Morgan 43rd Annual Healthcare Conference (January 2025) on 6ix